Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Paclitaxel + Ramucirumab
Synonyms
Therapy Description

Cyramza (ramucirumab) in combination with paclitaxel is FDA approved for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Ramucirumab Cyramza LY3009806 VEGFR2 Antibody 4 Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04069273 Phase II Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) Recruiting USA 0
NCT03081143 Phase II Paclitaxel + Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Ramucirumab Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (RAMIRIS) Active, not recruiting ITA | DEU | AUT 0
NCT03760822 Phase II Paclitaxel + Ramucirumab Ramucirumab Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE) Active, not recruiting FRA 0
NCT06203600 Phase II Paclitaxel + Ramucirumab Nivolumab + Paclitaxel + Ramucirumab Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Recruiting USA 0
NCT04604132 Phase Ib/II Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03) Terminated USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG 3
NCT04499924 Phase II Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib Paclitaxel + Ramucirumab + Tucatinib Paclitaxel + Ramucirumab Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02) Completed USA | GBR | CAN | AUS 2
NCT06043427 Phase II Paclitaxel + Ramucirumab Paclitaxel + Ramucirumab + Zanidatamab Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Recruiting CAN 0
NCT04704934 Phase III Paclitaxel + Ramucirumab Trastuzumab deruxtecan Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Active, not recruiting TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | BRA | BEL | ARG 10
NCT06038578 Phase II Paclitaxel + Ramucirumab + TRK-950 Paclitaxel + Ramucirumab A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer Recruiting USA 2
NCT03281369 Phase Ib/II Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Active, not recruiting USA | ISR | GBR | ESP | AUS 2
NCT06346392 Phase III Rivoceranib Trifluridine-tipiracil hydrochloride Paclitaxel + Ramucirumab Docetaxel Paclitaxel Irinotecan AZD0901 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Recruiting USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BRA 8
NCT05002127 Phase II Paclitaxel + Ramucirumab + Trastuzumab Paclitaxel + Ramucirumab Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06) Recruiting USA | ITA | GBR | FRA | ESP | CZE | BEL | AUS 4
NCT04205968 Phase II Fluorouracil + Irinotecan + Leucovorin Paclitaxel + Ramucirumab Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers Recruiting USA 0
NCT02934464 Phase III Paclitaxel + Ramucirumab Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (ARMANI) Unknown status ITA 0
NCT04660760 Phase II Paclitaxel + Ramucirumab Ramucirumab + Trifluridine-tipiracil hydrochloride Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Recruiting USA 0
NCT06445972 Phase Ib/II Paclitaxel + Ramucirumab Paclitaxel + SKB264 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Recruiting USA | NOR | ITA | FRA | DEU | CHE | BRA 4
NCT03704077 Phase II Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma Withdrawn USA | ROU | ITA | ESP | DEU | CAN | BRA | AUS | ARG 5


Additional content available in Icon for CKB-BoostCKB BOOST